Conversations in Cardiology: Advances in Difficult-to-Treat and Resistant Hypertension

Activity Chair

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor, Tulane University School of Medicine
New Orleans, LA

Faculty

David A. Calhoun, MD
Professor of Medicine
Medical Director, Vascular Biology and Hypertension Program
The University of Alabama at Birmingham
Birmingham, AL

Carl (Chip) Lavie, Jr, MD, FACC, FACP, FCCP
Medical Director, Cardiac Rehabilitation and Preventive Cardiology
Director, Exercise Laboratories
John Ochsner Heart and Vascular Institute
Professor of Medicine
Ochsner Clinical School-The University of Queensland School of Medicine
New Orleans, LA

Overview

According to a 2018 American Heart Association Scientific Statement, 10.3 million US adults have treatment-resistant hypertension. It has been shown that these adults are at a markedly increased risk for cardiovascular target organ damage and cardiovascular events. Therefore, it is of considerable interest that novel approaches to treatment-resistant hypertension are being developed and evaluated in clinical trials. This program will review recent evidence regarding the impact of treatment-resistant hypertension and its contribution to cardiovascular risk, as well as assess the efficacy of conventional pharmacotherapeutic regimens and emerging therapies for treatment-resistant hypertension.

Agenda

12:00 PM
Registration and Lunch

12:30 PM
Introduction and Pretest
Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA

12:35 PM
Resistant Hypertension: Definitions and Identification
David A. Calhoun, MD

12:47 PM
Therapeutic Lifestyle Interventions for High-Risk Patients With Hypertension
Carl (Chip) Lavie, Jr, MD, FACC, FACP, FCCP

12:59 PM
Evidence-based Pharmacotherapy for Resistant Hypertension
David A. Calhoun, MD

1:16 PM
Emerging Therapies for Difficult-to-Treat and Treatment-Resistant Hypertension
Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA

1:33 PM
Posttest

1:38 PM
Panel Discussion and Question and Answer

2:00 PM
Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Review recent evidence regarding the impact of treatment-resistant hypertension and its contribution toward cardiovascular risk.

• Assess the efficacy of conventional non-pharmacologic and pharmacotherapeutic regimens used to treat treatment-resistant hypertension.

• Evaluate new clinical findings regarding the mechanisms of action, safety, and efficacy of emerging therapies for treatment-resistant hypertension.

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with treatment-resistant hypertension.

Collaborative partners: Vindico Medical Education and the Association of Black Cardiologists

This live activity is not approved for AMA PRA Category 1 Credit(s)™.

This educational program has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME).

This activity is supported by an independent educational grant from Quantum Genomics, Inc.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support,all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.